姜黄素对模型大鼠肠粘膜炎症因子的调控

南方医科大学学报 ›› 2004, Vol. 24 ›› Issue (12): 1353-1358.

姜黄素对模型大鼠肠粘膜炎症因子的调控

简燕婷¹, 王继德¹, 麦国丰², 张亚历¹, 赖卓胜¹

1. 南方医科大学南方医院消化研究所, 广东, 广州, 510515;
2. 江门市卫生局江门市红十字会诊疗所, 广东, 江门, 529000

出版日期:2004-12-20 发布日期:2004-12-20
基金资助:
收稿日期:2004-5-19。
基金项目:国家自然科学基金(30270078);广东省中医药基金(1040191);
作者简介:简燕婷(1967- ),女,副教授,1990年毕业于广州医学院,现为南方医科大学南方医院消化内科博士研究生,电话:020-61641544,E-mail:jyt821_jyt821@yahoo.com.cn.
通讯作者:张亚历,男,教授,博士研究生导师,E-mail:zhangyl@fimmu.com

Modulation of intestinal mucosal inflammatory factors by curcumin in rats with colitis

JIAN Yan-ting¹, WANG Ji-de¹, MAI Guo-feng², ZHANG Ya-li¹, LAI Zhuo-sheng¹

1. 南方医科大学南方医院消化研究所, 广东, 广州, 510515;
2. 江门市卫生局江门市红十字会诊疗所, 广东, 江门, 529000

Online:2004-12-20 Published:2004-12-20

摘要/Abstract

摘要： 目的炎症性肠病(inflam matory bowel disease,IBD)肠道粘膜炎症与转录因子核因子-κappaB(NF-κB)密切相关。该研究探索NF-κB抑制剂姜黄素IBD动物模型大鼠大肠粘膜炎症因子调控的机制。筛选IBD的靶向治疗药物。方法建立以5%三硝基苯磺酸(5%TNBS)诱导的肠炎大鼠模型,肠炎的大鼠给予含2.0%的姜黄素饲料,药物阳性对照组给予含0.5%柳氮磺胺吡啶(SASP)的饲料,模型组及阴性对照组给予普通饲料。评价病理组织学评分的变化。应用半定量RT-PCR检测炎症因子mRNA的表达。结果姜黄素改善肠炎模型大鼠病理组织学症象。姜黄素可显著抑制肠炎模型大鼠肠粘膜致炎因子IL-1βmRNA的高表达,同时可显著提高抗炎因子IL10mRNA的低表达,抗炎因子IL-4mRNA在各组均未见表达。结论研究显示,NF-κB抑制剂姜黄素可调控IBD鼠科模型中的炎症因子IL-1βmRNA和IL-10mRNA表达。姜黄素有可能是一种有潜能的IBD的靶向药物。

Abstract: Objective To explore the mechanism of modulation of intestinal mucosal inflammatory factors by curcumin, the inhibitor of the transcriptional factor nuclear factor -κB (NF-κB), in rats with trinitrobenzene sulfonic acid (TNBS)-induced colitis, and screen for a targeted therapeutic agent for treatment of inflammatory bowel disease (IBD). Methods Rats with TNBS-induced colitis were fed with diet containing 2.0% curcumin (treatment group), 0.5% sulfasalazine (SASP, positive control group), and normal diet (model group and negative control group). Changes in colonic mucosal histological scores were evaluated and the cytokine mRNA expressions in the colonic tissue assessed by semiquantitative reverse transcriptional PCR (RT-PCR). Results Treatment with curcumin ameliorated the histopathologic signs in rats with TNBS-induced intestinal inflammation. Curcumin and sulfasalazine obviously suppressed the high expression of proinfiammatory cytokine interleukin (IL)-1β mRNA and increased the low expression of IL-10 mRNA in the colonic mucosa. Expression of the anti-inflammatory cytokine IL-4 mRNA was detected in none of the groups. Conclusions Curcumin could modulate the expressions of IL-1β and IL-10 mRNA in murine model of IBD, which suggests the potential of curcumin as a targeted therapeutic agent for IBD.

中图分类号:

R285.5

简燕婷¹, 王继德¹, 麦国丰², 张亚历¹, 赖卓胜¹. 姜黄素对模型大鼠肠粘膜炎症因子的调控[J]. 南方医科大学学报, 2004, 24(12): 1353-1358.

JIAN Yan-ting¹, WANG Ji-de¹, MAI Guo-feng², ZHANG Ya-li¹, LAI Zhuo-sheng¹. Modulation of intestinal mucosal inflammatory factors by curcumin in rats with colitis[J]. Journal of Southern Medical University, 2004, 24(12): 1353-1358.

参考文献

[1] Kinoshita K, Sato K, Hori M, et al. Decrease in activity of smooth muscle L-type Ca²⁺ channels and its reversal by NF-kappaB inhibitors in Crohn’s colitis model [J]. Am J Physiol Gastrointest Liver Physiol, 2003, 285 (3):G483-93.
[2] Monaco C, Andreakos E, Kiriakidis S, et al. Canonical pathway of nuclear factor κappa B activation selectively regulates proinflammatory and prothrombotic responses in human atherosclerosis [J].Proc Natl Acad Sci USA, 2004, 101(15): 5634-9.
[3] LappasM, YeeK, PermezelM, et al. Sulphasalazine and BAY 11-7082 interfere with the NF-kappa B and IKK-beta pathway to regulate the release of pro-inflammatory cytokines from human adipose tissue and skeletal muscle, In Vitro [J]. Endocrinology,2004, [Epub chead of print].
[4] Jobin C, Bradham CA, Russo MP, et al. Curcumin blocks cytokinemediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-κ appa B kinase activity[J]. J Immunol, 1999,163(6):3474-83.
[5] Neurath MF, Fuss I, Kelsall BL, et al. Antibodies to interleukin 12 abrogate established experimental colitis in mice [J]. J Exp Med,1995, 182(5): 1281-90.
[6] Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease[J]. Nature, 2001,411(6837):599-603.
[7] Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease [J]. Nature,2001, 411(6837): 603-6.
[8] Ogura Y, Inohara N, Benito A, et al. Nod2, a Nod1/Apaf-1 family member that is restricted to monocytes and activates NF-kappaB [J].J Biol Chem, 2001, 276(7): 4812-8.
[9] Monteleone G, Mann J, Monteleone I, et al. A failure oftransforming growth factor-betal negative regulation maintains sustained NF-κ appaB activation in gut inflammation[J]. J Biol Chem, 2004,279(6):3925-32.
[10] Cui HH, Chen CL, Wang JD, et al. Effects of probiotic on intestinal mucosa of patients with ulcerative colitis [J]. World J Gastroenterol,2004, 10(10): 1521-5.
[11] Ferretti M, Casini Raggi, Vpizarro TT, et al. Neutralization of endogenous IL1 receptor antagonist exacerbates and prolongs inf lammation in rabbit immune colitis [J]. J Clin Invest, 1994, 94(1):449-53.
[12] Bickston S J, Cominelli F. Recombinant interleukin 10 for the treatment of active Crohn’s disease: lessons in biologic therapy [J].Gastroenterology, 2000, 119(6): 1781-3.
[13] Shibata Y, Taruishi M, Ashida T. Experimental ileitis in dogs and colitis in rats with trinitrobenzene sulfonic acid--colonoscopic and histopathologic studies [J]. Gastroenterol Jpn, 1993, 28(4): 518-27.
[14] Dijkstra G, Moshage H, Jansen PL. Blockade of NF-κ appaB activation and donation of nitric oxide: new treatment options in inflammatory bowel disease [J]? Scand J Gastroenterol Suppl, 2002,(236): 37-41.
[15] Jobin C, Bradham CA, Russo MP, et al. Curcumin blocks cytokinemediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-κ appa B kinase activity[J]. J Immunol, 1999, 163(6): 3474-83.
[16] Baldwin AS. The NF-κB and IκB proteins: new discoveries and insights [J].Annu Rev Immunol, 1996, 14: 649-83.